Assembly Biosciences (NASDAQ:ASMB) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
With 32% ownership, Assembly Biosciences, Inc. (NASDAQ:ASMB) has piqued the interest of institutional investors [Yahoo! Finance]
Assembly Biosciences (NASDAQ:ASMB) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Re
Assembly Biosciences (NASDAQ:ASMB) was given a new $40.00 price target on by analysts at Mizuho.